Trial | NCT03566589  Report issue

Title

Effects of PS128 on Parkinsonian Symptoms
Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    30
The purpose of this study is to examine the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.
This study is designed to examine the extent to which L. plantarum PS128 can improve symptoms in PD patients. L. plantarum PS128 is a psychobiotic that regulates the level of dopamine in specific brain regions. Patients with PD will receive PS128 treatment for 12 weeks. Symptoms of PD will be clinically evaluated before and after the treatment, and the results will be compared.
Study Started
Jul 02
2018
Primary Completion
Nov 09
2018
Study Completion
Dec 30
2018
Last Update
Mar 10
2021

Dietary Supplement Lactobacillus plantarum PS128

daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)

  • Other names: PS128

PS128 Experimental

daily ingestion of Lactobacillus plantarum PS128 capsules

Criteria 

Inclusion Criteria:

Between ages of 40-80 years old
Diagnosed as a patient with Parkinson's disease of modified Hoehn and Yahr Stage between 1 and 2.5 as rated during an "on" period

Exclusion Criteria:

Patients on antibiotics within the preceding one month
Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
Have current or history of inflammatory bowel disease
Have history of cancer
Have undergone surgery of liver, bladder, or gastrointestinal tract
Known allergy to probiotics
Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
Have received deep brain stimulation
Patients receiving artificial enteral or intravenous nutrition
No Results Posted